REG - AstraZeneca PLC - AZ COMPLETES SELOKEN AGREEMENT WITH RECORDATI <Origin Href="QuoteRef">AZN.L</Origin>

AstraZenecaAnnouncement

03/07/2017 07:00

RNS Number : 8401J
AstraZeneca PLC
03 July 2017
3 July 2017 07:00 BST
ASTRAZENECA COMPLETES AGREEMENT
WITH RECORDATI FOR SELOKEN IN EUROPE
AstraZeneca announced today that it has completed* the previously-communicated agreement with Recordati S.p.A (Recordati) for the commercial rights to Seloken/Seloken ZOK(metoprolol tartrate and metoprolol succinate, respectively)and associated Logimax fixed-dose combination (metoprololsuccinate and felodipine) medicines in Europe. Metoprolol succinate is a beta-blocker for the control of hypertension, angina and heart failure.
Based on the limited level of ongoing interest that AstraZeneca will retain in the medicines in Europe, the upfront and tiered royalty payments received from Recordati will be reported as Other Operating Income in the Company's financial statements. An upfront payment of $290 million will be accounted for in the second quarter of 2017.
*With the exception of Romania, which is subject to separate closing.
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca.comand follow us on Twitter @AstraZeneca.
Media Relations
Esra Erkal-Paler
UK/Global
+44 203 749 5638
Karen Birmingham
UK/Global
+44 203 749 5634
Rob Skelding
UK/Global
+44 203 749 5821
Jacob Lund
Sweden
+46 8553260 20
Michele Meixell
US
+1 302 885 2677
Investor Relations
Thomas Kudsk Larsen
+44 203 749 5712
Craig Marks
Finance, Fixed Income, M&A
+44 7881 615 764
Henry Wheeler
Oncology
+44 203 749 5797
Mitchell Chan
Oncology
+1 240 477 3771
Lindsey Trickett
Cardiovascular & Metabolic Diseases
+1 240 543 7970
Nick Stone
Respiratory
+44 203 749 5716
Christer Gruvris
Autoimmunity, Neuroscience & Infection
+44 203 749 5711
US toll free
+1 866 381 7277
Adrian Kemp
Company Secretary
AstraZeneca PLC

This information is provided by RNS
The company news service from the London Stock Exchange
  END
AGRRTMRTMBJMMJR